Catherine Tangen

Featured in: Favicon

jamanetwork.com Favicon

thelancet.com Favicon

aacrjournals.org Favicon

europeanurology.com (+1) Favicon

clincancerres.aacrjournals.org

Articles

Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial

May 29, 2024 | europeanurology.com | Catherine Tangen |Elisabeth I. Heath |Mark Stein

Abstract EVEREST is a phase 3 trial in patients with renal cell cancer (RCC) at intermediate-high or very high risk of recurrence after nephrectomy who were randomized to receive adjuvant everolimus or placebo. Longer recurrence-free survival (RFS) was observed with everolimus (hazard ratio [HR] 0.85, 95% confidence interval [CI] 0.72–1.00; p = 0.051), but the nominal significance level (p = 0.044) was not reached.
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial

Jul 28, 2023 | thelancet.com | Christopher Ryan |Catherine Tangen |SWOG Statistics |Elisabeth I. Heath

Background Patients undergoing resection of renal cell carcinoma are at risk of disease relapse. We evaluated the effectiveness of the mammalian target of rapamycin inhibitor everolimus administered after surgery.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →